JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
July 30, 2015 7:00 AM EDTRevenues of $5.0 billion, in line with the second quarter of 2014. Non-GAAP operating income of $1.6 billion, an increase of 16% compared to the second quarter of 2014. GAAP operating income of $662 million, down 28%. Non-GAAP net income of $1.2 billion, up 15% compared to the second quarter of 2014. GAAP net income of $539 million, a decrease of 28%. Quarterly non-GAAP EPS of $1.43, an increase of 14% compared to the second quarter of 2014. GAAP diluted EPS of $0.63, a decrease of 28%. Strong cash flow from operations of $1.5 billion, an increase of 41%... More
